Idioma:

Clinicians’ Guide to Cannabidiol and Hemp Oils

VanDolah, Harrison J. ; Bauer, Brent A. ; Mauck, Karen F.

Mayo Clinic proceedings, 2019-09, Vol.94 (9), p.1840-1851 [Periódico revisado por pares]

England: Elsevier Inc

Texto completo disponível

Citações Citado por

Enviar para

Título:
Clinicians’ Guide to Cannabidiol and Hemp Oils
Autor: VanDolah, Harrison J. ; Bauer, Brent A. ; Mauck, Karen F.
Assuntos: Addictions ; Attitude of Health Personnel ; Backup software ; Cancer Pain - drug therapy ; Cannabidiol ; Cannabidiol - administration & dosage ; Cannabinoids ; Cannabis ; Cannabis products ; Cannabis sativa ; Chronic Pain - drug therapy ; Drug abuse ; Drug Approval ; Edible oils ; Epilepsy ; FDA approval ; Federal regulation ; Female ; Hemp ; Homeostasis ; Humans ; Male ; Marijuana ; Medical marijuana ; Medical Marijuana - therapeutic use ; Nabilone ; Narcotics ; Oils ; Opioids ; Pain ; Patients ; Practice Guidelines as Topic ; Tetrahydrocannabinol ; United States ; United States Food and Drug Administration
É parte de: Mayo Clinic proceedings, 2019-09, Vol.94 (9), p.1840-1851
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Descrição: Cannabidiol (CBD) oils are low tetrahydrocannabinol products derived from Cannabis sativa that have become very popular over the past few years. Patients report relief for a variety of conditions, particularly pain, without the intoxicating adverse effects of medical marijuana. In June 2018, the first CBD-based drug, Epidiolex, was approved by the US Food and Drug Administration for treatment of rare, severe epilepsy, further putting the spotlight on CBD and hemp oils. There is a growing body of preclinical and clinical evidence to support use of CBD oils for many conditions, suggesting its potential role as another option for treating challenging chronic pain or opioid addiction. Care must be taken when directing patients toward CBD products because there is little regulation, and studies have found inaccurate labeling of CBD and tetrahydrocannabinol quantities. This article provides an overview of the scientific work on cannabinoids, CBD, and hemp oil and the distinction between marijuana, hemp, and the different components of CBD and hemp oil products. We summarize the current legal status of CBD and hemp oils in the United States and provide a guide to identifying higher-quality products so that clinicians can advise their patients on the safest and most evidence-based formulations. This review is based on a PubMed search using the terms CBD, cannabidiol, hemp oil, and medical marijuana. Articles were screened for relevance, and those with the most up-to-date information were selected for inclusion.
Editor: England: Elsevier Inc
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 8 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Clinicians’ Guide to Cannabidiol and Hemp Oils

VanDolah, Harrison J. ; Bauer, Brent A. ; Mauck, Karen F.

England: Elsevier Inc

Buscando em bases de dados remotas. Favor aguardar.